Download this clinical

Title: Double Blind Placebo-Controlled Study with Kevis Lotion

Kevis Summary:

In this experiment, which allows a casual interpretation for comparable groups, the effectiveness of Kevis in comparison with a placebo is revealed in a statistically significant manner.

Findings:

On the percentage of telogen hairs: in 90 days it decreases by 16% in the Kevis group, and only by 6% in the placebo group.

On the number of hairs counted in the three comb-stroke test: (a) in the Kevis group it decreases by 56% in 60 days and by 59% in 90 days; (b) in the placebo group it only decreases by 18% in 60 days and by 16% in 90 days.

On the number of hairs pulled out in the traction test: (a) in the Kevis group it decreases by 29% in 60 days and by 47% in 90 days, (b) in the placebo group it only decreases by 5% in 60 days and by 7% in 90 days.

Clinical Institution: Hotel-Dieu, Marseille, France.

Director: Y. Privat

 Download this clinical

Title: Les Nouvelles Dermatologiques 18-19 May. 1990 (Marseille, France).
Localization of 5-alpha-dihydro-testosterone in the hair follicle: employment of monoclonal antibodies in the evaluation of the anti androgenetic activity of H.U.C.P.

Kevis Summary:

When the researchers of this study investigated the sections of test subjects’ scalps which were not treated with the Kevis patented hyaluronan, HUCP, they found the hair follicles in those sections had a high presence of 5-alpha-DHT in the external follicle sheath and no apparent similar presence in the cellular matrix. However, in the telogen (resting phase) follicles contained within a number of test sections, there was evidence of a certain presence of 5-alpha-DHT also in the cellular matrix, always associated with the presence of 5-alpha-DHT in the follicle sheath.

Findings:

Observation of the sections obtained from the biopsies taken in the skin areas subjected to the HUCP revealed an almost total absence of 5-alpha-DHT, both in the external sheath and the follicular matrix. These findings were evident in all the subjects involved in the investigation. Indicating that HUCP removes DHT from the hair follicle.

Clinical Institution: University of Pavia, School of Dermatology, Milan, Italy.

Researcher(s): E. Berardesca, L. Miori, G. Rabbiosi, R. Venafra.

 Download this clinical

Title: Local Treatment of Androgenetic Alopecia with Kevis: An International Post-Marketing Survey on the Results of Clinical Trials in Patients Treated for up to One Year. (Unpublished)

Kevis Summary:

Seven of the top dermatologists throughout Europe (Italy, France, England, Finland and Spain) did a follow-up on 159 patients who used Kevis for up to one year during 1987 through 1990 to determine the safety and effectiveness of Kevis. 62.3% of the patients used Kevis for a full year and the average time of use was approximately 9 months.

To determine the effectiveness they used Traction Test (pulling test) to determine the reduction in hair coming out and Judgment (by the Doctor) of the Overall Condition of the hair and Judgment (by the Patient) of: Hair Loss, Appearance, Texture, Manageability and Look of Fullness.

Findings:

In the Conclusion section of this study they wrote “In fact, use of the preparation by both males and females, regardless of the actual alopecic [hair loss] pattern, was not only effective in a wide majority of cases (approx. 90%), but also practically devoid of any risk of side effects.”

They also commented in this study that “Although the effects of treatment generally appear fairly soon, it must be noted that the best results are obtained progressively. It is, therefore, advisable to continue treatment for the recommended period, even if there is a delay in obtaining evident results.”

Title: Local Treatment of Androgenetic Alopecia with Kevis

Researcher(s): Benveniste M.J., Dermatologist, Hotel Dieu, University of Marseille, France Di Vincenzo R., Dermatologist, Varese Gimenez Camarasa J.M., Dermatologist, Hospital Del Mar, University of Barcellona, Spain Fenton D., Senior Registrar, St. Thomas’ Hospital, London, U.K. Peyri Rey J., Head of Dermatology, residencia Sanitaria de la Seguridad Principes de España, Barcellona, Spain Reunala T., Dept. of Clinical Sciences, University of Tampere, Finland Soragni A., Dermatologist, Varese, Italy Venafra R., R. & D. Director, Farmaka Research Centre Poma A., Clinical Research Associate, Milan Italy

Unpublished

 Download this clinical

Title: Report of a Treatment with Topical Solution of the Product Named "Kevis" used for Subjects Suffering from Defluvium and/or Alopecia.

Kevis Summary:

A favorable evaluation of the topical solution was expressed by patients about "acceptance" of the product: very good for 41% of the patients, with only one unsatisfied patient. The same favorable evaluation was given by patients about efficacy: very good or good for 60% of the patients, while an unfavorable opinion was uttered by 3 patients (7%).

The clinical evaluation expressed by the dermatologist was that the Kevis treatment was very favorably in 26% of the cases versus 21% of the cases, where it was not possible to observe any effect. 59% of the cases experienced modest positive effects.

Findings:

After use for 60-90 days, the topical product applied in 43 male and female subjects suffering from slight or moderate degree alopecia has exerted an action which may be globally defined as favorable; this positive evaluation is justified by the microscope finding that has evidenced a significant increase of hair in active growth phase (anagen) after application of Kevis topical solution.

As to pruritus (itching), the preparation has shown to be effective against this symptom, with statistically significant result, but three cases where drawbacks were present (onset or increase). On the other hand, the preparation has shown to be poorly suitable for the treatment of pityriasis scaling: patients who obtained improvement are counterbalanced by patients where a limited enhancement of scaling had appeared, so that the comparison did not result as statistically significant.

After performance of traction test, the number of subjects who presented an intense or very intense defluvium was halved, with a markedly significant improvement after treatment. At last, the drawbacks connected to use of the topical product have appeared to be limited: in 9% cases, increase of pityriasis scaling, and in 7% cases, onset or increase of pruritus.

Clinical Institution: University of Pavia, Dermatology Clinic July 1, 1985

Director: Professor G. Rabbiosi

 Download this clinical

Title: La Medicina Estetica numero 4, 1986 (Editrice Salus Internazionale-Roma) Action of a topical product on the scalp

Kevis Summary:

43 patients affected by telogen effluvium (hair loss) were subjected to treatment with a preparation for topical use. The parameters evaluated were: resistance to traction and trichogram; evolution of seborrhea, pruritus and dandruff. The results were evaluated through patient's subjective judgment and his/her acceptance of the treatment.

Findings:

From the statistical elaboration of the data obtained, it can be concluded that the topical product exerts a favorable action in deterring defluvium and seborrhea.

Clinical Institution: University of Pavia, Dermatology Clinic

Director: G. Rabbiosi

 Download this clinical

Title: La Medicina Estetica number 3, 1988 (Editrice Salus Internazionale-Roma).

Kevis Summary:

A double blind trial of Kevis topical solution against placebo used in the treatment of post-partum telogen effluvium. A total of 50 women, aged between 20 and 35 years, primarily new mothers, affected by post partum telogen effluvium, were divided into two randomized groups of 25, and treated, in double blind conditions, for a period of 36 days, with a topical product indicated to prevent hair loss, compared with a placebo.

Findings:

The results, analyzed by the trichogram method and traction test, demonstrated the efficacy of Kevis in bringing about the return of a hair-producing physiological state, while excellent tolerability confirmed the product’s safety.

Clinical Institution: Maggiore Hospital of Lodi, Italy

Director: Professor Mario Goisis

 Download this clinical

Title: La Medicina Estetica number 1, 1988 (Editrice Salus Internazionale-Roma).

Kevis Summary:

Report on the treatment with Kevis topical preparation, of volunteers affected by neoplasia (cancer) and subjected to cycles of chemotherapy with cytostatic drugs. In a clinical study performed on 61 patients subjected to chemotherapy, a group of 32 patients received topical treatment with a new anti-alopecic preparation (Kevis), while 29 patients who did not receive topical treatment were used as the control group.

Findings:

Based on the resultant objective observations (photographs, traction test), it was statistically demonstrated that Kevis is active, firstly, in slowing down drastic hair loss caused by chemotherapy, and secondly, in aiding the conditions of the scalp to return to the normal physiological state of hair production at the end of the chemotherapy cycle.

Clinical Institution: "S. Anna" Province General Hospital, Como, Italy

Director: Dr. Cosimo Epifani